Abstract
While accumulating clinical trials have focused on the impact of cell therapy in patients with acute myocardial infarction (MI) and ischemic cardiomyopathy, there are fewer efforts to examine cell-based therapy in patients with non-ischemic cardiomyopathy (NICM). We hypothesized that cell therapy could have a similar impact in NICM. The POSEIDON-DCM trial is a phase I/II trial designed to address autologous vs. allogeneic bone marrow-derived mesenchymal stem cells (MSCs) in patients with NICM. In this study, cells will be administered transendocardially with the NOGA injection-catheter system to patients (n = 36) randomly allocated to two treatment groups: group 1 (n = 18 auto-human mesenchymal stem cells (hMSC)) and group 2 (n = 18 allo-hMSCs). The primary and secondary objectives are, respectively, to demonstrate the safety and efficacy of allo-hMSCS vs. auto-hMSCs in patients with NICM. This study will establish safety of transendocardial injection of stem cells (TESI), compare phenotypic outcomes, and offer promising advances in the field of cell-based therapy in patients with NICM.
Original language | English (US) |
---|---|
Pages (from-to) | 769-780 |
Number of pages | 12 |
Journal | Journal of Cardiovascular Translational Research |
Volume | 7 |
Issue number | 9 |
DOIs | |
State | Published - Nov 25 2014 |
Externally published | Yes |
Keywords
- Bone marrow cells
- Dilated cardiomyopathy
- Heart failure
- Stem cells
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Genetics
- Genetics(clinical)
- Molecular Medicine
- Pharmaceutical Science